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The diagnosis of multiple myeloma can be challenging, even forexperienced physicians, and requires close collaboration betweennumerous disciplines (orthopedics, radiology, nuclear medicine,
radiation therapy, hematology and oncology) before the final diagnosis of
myeloma is made. The definition of multiple myeloma is based on the
presence of clinical, biochemical, histopathological, and radiological
markers of disease. Specific tests are needed both at presentation and dur-
ing follow-up in order to reach the correct diagnosis and characterize the
disease precisely. These tests can also serve prognostic purposes and are
useful for follow-up of myeloma patients. Molecular analyses remain piv-
otal for defining high-risk myeloma and are used in updated patient strat-
ifications, while minimal residual disease assessment via flow cytometry,
molecular techniques and radiological approaches provides additional
prognostic information on patients’ long-term outcome. This pivotal
information will guide our future treatment decisions in forthcoming
clinical trials. The European Myeloma Network group updated their
guidelines on different diagnostic recommendations, which should be of
value to enable appropriate use of the recommendations both at diagno-
sis and during follow-up.
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ABSTRACT
Introduction
The classification and differential diagnosis of mono-
clonal gammopathies is based on clinical, biological and
radiological criteria but remains challenging in certain
cases. Multiple myeloma (MM) is the most common
malignant gammopathy and is associated with a wide
spectrum of signs and symptoms.1 In the past decade, the
treatment options for patients with MM have increased
considerably. Together with improved supportive care,
these new regimens significantly prolong the survival of
both younger and older patients.2 The 2014 revision of the
diagnostic criteria for MM allows the initiation of treat-
ment in patients defined only by biomarkers, annotated as
SLIM criteria [bone marrow (BM) infiltration >60%,
involved/uninvolved serum free light-chain (SFLC) ratio
>100 or >1 focal lesion >5 mm as determined by magnetic
resonance imaging (MRI)], without waiting for conven-
tional CRAB criteria (hypercalcemia, renal impairment,
anemia, bone disease) to occur.3,4 Both the SLIM biomark-
er and CRAB criteria are listed in Figure 1. Given the
recent evolution in diagnosis and response assessment,
members of the European Myeloma Network (EMN)
agreed to review and recommend diagnostic and response
criteria to allow their discriminating use in daily practice
and current care of patients’ .
Methodology
These recommendations were developed by a panel of
clinical experts on MM based on evidence of published
data through August 2017. Expert consensus was used to
suggest recommendations, where sufficient data were
lacking. The final recommendations were classified based
on the GRADE criteria,5 which incorporates the strength
and quality of evidence (Online Supplementary Table S1).
Based on discussions at the 2017 EMN Trialist meeting
(Baveno, Italy) guidelines were prepared and circulated
among all panel members. The manuscript subsequently
underwent revision in three rounds until the EMN experts
reached consensus. In line with the guidelines of the
International Committee of Medical Journal Editors,
authorship was based on active contribution during dis-
cussion, writing and revision of the guidelines.
European Myeloma Network recommendations
Diagnostic tools
Blood tests
A defining feature of plasma cell (PC) disorders is the
secretion of monoclonal immunoglobulins, often referred
to as a monoclonal M-protein, which can be used as a
diagnostic marker, but also for the follow-up of the dis-
ease. Its heavy- and light-chain components can be identi-
fied by immunofixation and further quantified by serum
protein electrophoresis and/or a serum free light-chain
(SFLC) assay. It should be kept in mind that with persist-
ing disease and possible de-differentiation of myeloma
cells, the capacity to produce M-proteins may decrease or
be completely lost (light-chain escape). In those patients,
low M-protein levels, the presence of light chains only, or
even complete absence of M-proteins and light chains
may be mistaken as an ongoing or evolving response.6
Of note, immunofixation is approximately 10-fold more
sensitive than serum protein electrophoresis and is
required at diagnosis to characterize the phenotype of the
M-protein, and for confirmation of a complete response,
which is defined as being immunofixation-negative.7
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Figure 1. The differential diagnosis between monoclonal gammopathy of undetermined significance, smoldering myeloma and multiple myeloma. The discrimi-
nation between these monoclonal gammopathies is based on: (i) the plasma cell infiltration in the bone marrow, (ii) the presence of clinical symptoms related to
myeloma disease and (iii) the existence of biomarkers of disease that allow initiation of treatment. MGUS: monoclonal gammopathy of undetermined significance;
SMM: smoldering multiple myeloma; MM: multiple myeloma; BM: bone marrow; PC: plasma cells; FLC: free light chain; MRI: magnetic resonance imaging.
Serum electrophoresis and immunofixation may not be
able to detect light-chain aberrations in patients with
oligo-secretory disease, such as light-chain MM. Due to
their low molecular weight, these SFLC are rapidly cleared
by the kidneys. In such cases, the monoclonal burden
should be measured in a 24 h urine collection or in the
serum by an automated SFLC immunoassay (Grade 1A),
the latter having a higher sensitivity to detect and quanti-
fy the involved free light chains.7 In concordance with the
International Myeloma Working Group (IMWG), we rec-
ommend the performance of serum immunofixation and
electrophoresis on serum and urine samples and a SFLC
assay for the diagnosis of a monoclonal PC disorder
(Grade 1A).
Additional laboratory tests should be performed for the
diagnosis and follow-up of MM patients, such as a com-
plete blood count to evaluate possible cytopenias, blood
smears to look for circulating PC and general biochem-
istry tests (renal and liver function tests, calcium, phos-
phate, uric acid, albumin, creatinine, lactate dehydroge-
nase, C-reactive protein, β2-microglobulin).
Quantification of serum immunoglobulins by nephelom-
etry enables an indirect measurement of the M-protein or
the recognition of a secondary hypogammaglobinemia
and is recommended for any patient presenting with a
gammopathy (oligo-, poly- or monoclonal) (Grade 1A).
The HevyLite® immunoassay quantifies both the
involved and uninvolved intact immunoglobulin chains
and quantifies them separately (IgGκ/λ, IgAκ/λ, IgMκ/λ).8
This assay has prognostic value for progression-free and
overall survival9 and seems particularly useful when the M-
protein is difficult to measure via serum protein elec-
trophoresis. This assay is not yet part of the routine
workup of MM patients, but may be of value in the follow-
up of patients and has been included in clinical trials.10
Urine analysis
Proteinuria should be assessed on urine samples from
all patients at diagnosis and during the follow-up. If pro-
teinuria is present, it should be quantified in a 24 h urine
collection. Total 24 h protein and Bence-Jones proteinuria
should be evaluated by densitometry, electrophoresis and
immunofixation. To detect low amounts of monoclonal
proteins, it is recommended that the urine is concentrated
200-fold.11 These 24 h urine collections are often inconsis-
tently performed, resulting in incomplete urine collection.
In addition, renal function can influence the accuracy of
the results, a fact which should be taken into considera-
tion when interpreting laboratory values. The SFLC assay
can be used for the follow-up of patients with light-chain
MM. A recent French study, focusing on patients with
light-chain MM, demonstrated that the SFLC assay is
superior to 24 h urine collection for: (i) identifying
patients with measurable disease, (ii) following their
response to initial therapy, and (iii) giving a prognostic
indication of the patients’ response and overall survival.12
This study included 113 patients with light-chain MM, all
of whom had an abnormal SFLC ratio and measurable
disease parameters in serum, while only 64% patients
had measurable M-proteins in the urine, as determined
by urine protein electrophoresis. Similar results were
found in 576 patients with light-chain MM from the UK
Myeloma IX and XI trials. The disease burden of the
patients with light-chain MM could be measured and
monitored by urine protein electrophoresis in 80% of
cases. Of the remaining patients 113 (97%) had involved
free light chains >100 mg/L, which was sufficient to
measure response to therapy.13 These two studies con-
firmed the importance of SFLC measurements to diag-
nose and monitor patients with light-chain or oligosecre-
tory MM. The replacement of urine studies by the SFLC
assay for all myeloma patients remains controversial,
since an Eastern Cooperative Oncology Group study on
399 MM patients (of whom only a minority had light-
chain MM disease) found only a weak correlation
between results of the SFLC assay and 24 h protein analy-
sis.14
In line with the IMWG guidelines,15 we recommend the
SFLC assay for the diagnosis and monitoring of patients
with oligosecretory disease (Grade 2B). However, for
patients with measurable urinary M-proteins, MM
should be monitored by 24 h urine collections. When
albumin is the dominant protein found in the urine, a
glomerulopathy (such as AL-amyloidosis or light-chain
deposition disease) should be excluded. The 24 h urine
collection remains important when results are discordant.
Bone marrow studies 
A BM aspirate enables quantification of infiltrating PC
and cytogenetic studies on purified PC. Unfortunately,
dilution by peripheral blood during aspiration or the pres-
ence of patchy disease (uneven distribution of MM cells
throughout the BM) may result in an underestimation of
tumor infiltration.16 We therefore recommend an addi-
tional BM trephine biopsy, which may generate comple-
mentary information (Grade 1B). A BM biopsy correctly
identified MM disease in 95% of symptomatic patients
with a low PC count on the initial BM smears.16 The cor-
rect quantification of BM PC is also important because of
the 60% cut-off as a biomarker of malignancy. The
IMWG earlier recommended retaining the highest PC
infiltration in case of discrepancy. Finally, the monoclon-
ality of PC in the diagnostic sample should be confirmed
by multiparameter flow cytometry or by immunohisto-
chemistry confirming light-chain restriction.
Flow cytometry of bone marrow cells
In cases of monoclonal gammopathies, the most rele-
vant information provided by multiparameter flow
cytometry is the identification and enumeration of neo-
plastic versus polyclonal BM PC. Regardless of the disease
category, these neoplastic PC share similar immunophe-
notypic features, which are distinct from those of normal
PC. Typically, CD38, CD138 and CD45 (together with
light scatter characteristics) are the best backbone mark-
ers for the discrimination of PC. In addition, expression of
CD19, CD56, CD117, CD20, CD28, CD27 and CD81,
together with cytoplasmic immunoglobulin light-chain
restriction, allows a clear discrimination between nor-
mal/reactive versus monoclonal PC17 and was used by the
EuroFlow consortium to create a standardized panel
allowing the quantification and immunophenotypic char-
acterization of neoplastic PC.18
Due to dilution and the sometimes patchy disease dis-
tribution, multiparameter flow cytometry often underes-
timates the infiltration but remains important for detec-
tion of monoclonal PC in the peripheral blood and for the
detection of minimal residual disease (MRD) in the BM.
The Mayo Clinic group reported on the prognostic
importance of circulating neoplastic cells in patients with
J. Caers et al.
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newly diagnosed or relapsing MM.19,20 They recently
monitored circulating MM cells at diagnosis and after
induction therapy by multiparameter flow cytometry and
confirmed inferior progression-free and overall survival




MM remains a heterogeneous disease with some
patients progressing rapidly, while others survive more
than 10 years. This clinical diversity is mainly driven by
genetic abnormalities affecting the biological characteris-
tics of MM cells.22 These alterations, summarized in Table
1, are important prognostic factors and can be divided
into primary, disease-initiating abnormalities (hyper-
diploidy and translocations involving the IGH locus) and
secondary events, related to further progression of the
disease.23 Fluorescence in situ hybridization on interphase
cells, performed after purification of CD138+ cells or after
counterstaining for the monoclonal light chains, is the
technique required to detect these abnormalities.24
Alternative techniques that can be used are single-
nucleotide polymorphism arrays, which are able to detect
loss of heterozygosity and numerical chromosome abnor-
malities, and comparative genomic hybridization arrays,
which mainly reveal numerical abnormalities.
Up to 65% of patients with MM have translocations
that involve the immunoglobulin heavy chain gene (IGH)
on chromosome 14q32. The prevalence and prognostic
impact of these IGH translocations vary according to the
partner chromosome (Table 1). Hyperdiploidy generally
consists of numerical gains (of the odd chromosomes)
with a few structural changes, and is usually associated
with longer overall survival. Not all trisomies have the
same prognostic impact: trisomy 21 impairs, while tri-
somies 3 and 5 improve overall survival and may partially
abrogate the negative impact of del17p and t(4;14).25
The most recurrent secondary alterations are dele-
tion/monosomy of chromosome 13, deletion of chromo-
some 17p13, chromosome 1 abnormalities (1p deletions
and 1q gains/amplifications), and C-MYC translocations.
Deletion 17p13 is considered the most detrimental prog-
nostic factor (due to short remission after high-dose ther-
apy and an increased incidence of extramedullary dis-
ease) and is present in 8-10% of untreated patients.26
This deletion becomes clinically relevant when identified
in the majority of PC. Different percentages (varying
from 10%-60%) have been proposed to define a thresh-
old that is associated with an impaired prognosis.27-29 The
presence of a biallelic inactivation (i.e. by an additional
mutation) of TP53 may particularly shorten overall sur-
vival.30 Aberrations of chromosome 1 (either 1q21
gains/amplifications or deletions of 1p32) are common
and associated with shorter progression-free and overall
survival, particularly the less frequent del(1p32).31
Patients with adverse cytogenetics may have additional
aberrations: in the British MRC IX trial patients with two
adverse cytogenetic lesions had a median overall survival
of 2 years, while the survival of patients with three aber-
rations (an adverse IGH translocation, +1q21 and
del17p13) was only 9 months.32 This inferior survival of
patients with additional genetic abnormalities was also
found in an Intergroupe Francophone du Myelome study that
focused on patients with either del17p13 or t(4;14): for
patients harboring t(4;14), multivariate analyses showed
Table 1. Recommended cytogenetic studies with implicated gene alterations and related prognosis.  
               Cytogenetics        Genetic event   Frequency         Prognosis                          Response to PI               Response to IMiD              Remarks                       Ref
Del17p13          P53                           5-15%  Independent marker,                                                   Negative prognostic          Negative prognostic             Most important          31, 60, 97
                                                                                                                   with negative impact           factor                                    factor                                        prognostic factor
                                                                                                                   on PFS and OS                                                                     Pomalidomide seems 
                                                                                                                                                                                                                     beneficial                                                                                 
             t(4;14)(p16.3;q32)             FGR3                   15%                 Independent marker,          Improves survival               Unfavorable for any                                                     27, 98-100
                                                            MMSET                                         with negative impact           compared to classic          IMiD
                                                                                                                   on PFS and OS                       agents                                                                                                                                       
Gain 1q21      CKS1B                       34-40% Independent marker,                                                   Negative prognostic          Negative prognostic             Might be directly             101
                                                                                                                   with negative impact           factor                                    factor                                        implicated in bortezomib
                                                                                                                   on PFS and OS                                                                                                                          resistance                            
Del 1p32, Del 1p22                        CDKN2C              7-17%               Independent marker,          Negative prognostic                                                                                                           102
                                                                                                                  with negative impact           factor
                                                                                                                   on PFS and OS                                                                                                                                                                        
              t(11;14)(q13;q32)             CCND1                 20%                 Good prognosis                     Good prognosis                  Good prognosis                      Sensitive                             103 
                                                                                                                                                                                                                                                                        to venetoclax                      
              t(14;16)(q32;q23)             CMAF                  2-3%                Controversial                                                                                                                            Considered as a              104
                                                                                                                                                                                                                                                                        negative prognostic 
                                                                                                                                                                                                                                                                        factor, but not confirmed 
                                                                                                                                                                                                                                                                        in IFM study                         
               Hyperdiploidy of                                            60%                 Standard prognosis,            Standard prognostic                                                            May neutralize the           25
odd chromosomes                                                                                unless associated with       factor                                                                                        negative prognostic
                                                                                                                   other negative prognostic                                                                                                     impact of del17p
                                                                                                                   markers                                                                                                                                      or t(4;14)                              
PFS: progression free survival, OS overall survival, FGFR3: fibroblast growth factor receptor 3, MMSET: multiple myeloma SET domain, PI proteasome inhibitor, IMiD: immunomodulatory drug,
CKS1B: CDC28 protein kinase regulatory subunit 1B, CDKN2C: cyclin-dependent kinase 4 inhibitor C, CCND1: cyclin-D1, MAF: musculoaponeurotic fibrosarcoma, IFM: Intergroupe Francophone du
Myelome
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a shorter overall survival for patients with a combined
del(13q14) or del(1p32). Among patients with del17p13,
overall survival was shorter in those with del(1p32).33
Next-generation genome sequencing
Next-generation sequencing allows the detection of
baseline clonal heterogeneity,34 clonal tiding35 and linear
and branching evolution and contributes to a better under-
standing of MM disease biology.36 The availability of more
than 2000 sequenced MM genomes has essentially
defined the genomic landscape. These data revealed a
high incidence of clinically relevant genomic aberrations,
including oncogenic RAS mutations, but also a number of
rarer and potentially actionable lesions, such as BRAF
mutations.37,38 Of note, the vast majority of available
genomic data in MM is still derived from samples
obtained at diagnosis and does not, therefore, necessarily
reflect the situation during disease progression. In addi-
tion, the clinical relevance of most mutations has not yet
been determined and is undergoing investigation in large
sequencing programs (CoMMpass, The Myeloma
Genome Project and others).39,40 No mutation screening
has yet been implemented in standard clinical workflows,
but mutational analyses may help to identify potential
therapeutic targets (such as BRAF mutations) and to strat-
ify of patients in clinical trials.
Gene expression profiling
Based on microarrays to study mRNA expression, gene
expression profiling gives a global snapshot of disease
biology and may help clinicians to classify patients into
separate groups with distinct outcomes. The University of
Arkansas pioneered this technique to stratify MM patients
and to characterize individuals’ disease at the molecular
level.41 They identified gene expression profiling patterns
that allowed MM patients to be grouped in seven disease
classes. Further correlation of their microarray results with
survival data of individual patients identified a list of 70
genes (GEP70) that had strong prognostic information.41
Similarly, the HOVON group identified a 92-gene signa-
ture (termed SKY92), based on the gene expression profil-
ing results of the Hovon-65 trial.42,43 Other gene expression
profiling-based risk models have been developed, such as
the IFM-15 and MRC-IX-6 gene signatures44,45 Although
not routinely determined in the majority of laboratories
within or outside Europe, both the GEP70 and the SKY92
profiles are commercially available.
Imaging
Traditionally, osteolytic bone disease was investigated
by conventional skeletal radiography. The 2014 IMWG
disease criteria also considered small osteolytic lesions (≥5
mm), detected by computed tomography (CT) or com-
bined 18F-fluorodeoxyglucose (18F-FDG) positron emission
tomography (PET/CT) as symptoms of myeloma-induced
bone disease.3 Taking into account these definitions, in
2015 the EMN proposed a relevant algorithm for guiding
the choice of imaging technique.46,47 Different European
centers have integrated CT into their diagnostic work-up
based on its superior sensitivity and its ease of operation
This choice was supported by the recent implementation
as a national standard of care in the diagnostic workup of
patients with suspected MM in the UK and elsewhere.48
Whole-body CT has also been integrated into the diagnos-
tic work-up of the European Society of Medical
Oncology49 and the upcoming IMWG guidelines. 
J. Caers et al.
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Table 2. Recommendations on further examinations at diagnosis, for response assessment, during follow-up and at relapse.
Diagnostic                 Tool                                                            Diagnosis                      At response                     At follow-up                   At relapse
site
                                          BM cytology and biopsy to                                Obligatory                          Obligatory*                         Not required                    Obligatory**
                                          confirm plasmacytosis and 
                                          monoclonality 
Bone marrow            Flow cytometry                                               Recommended                         Optional                             Not required                        Optional
                                          Cytogenetics                                                        Obligatory                         Not required                         Not required                        Optional
                                          Advanced techniques: GEP, NGS                      Optional                           Not required                         Not required                   Not required
                                          Blood count and blood smear                         Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          Serum electrophoresis and IF                        Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          Serum free light chain                              Recommended ***          Recommended ***            Recommended ***       Recommended ***
Blood                             Serum immunoglobulin levels                        Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          Renal and liver function tests                         Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          Calcium                                                                 Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          Lactate dehydrogenase                                     Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          Albumin, β2-microglobulin                              Obligatory                       Recommended                     Recommended                    Obligatory
                                          Urine sample to check for                               Obligatory                            Obligatory                              Obligatory                        Obligatory
                                          proteinuria and Bence-Jones 
Urine                            proteins 
                                          24 h urine collection                                     Recommended†                 Recommended†                   Recommended†              Recommended†
                                        Low dose whole-body CT                            Recommended††                   Not required                   When symptomatic            Recommended
Imaging                       PET/CT                                                                    Optional                             Optional†††                     When symptomatic                  Optional
                                          Whole-body MRI                                                   Optional                           Not required                   When symptomatic                  Optional
BM: bone marrow; GEP: gene expression profiling; IF: immunofixation; NGS: next generation sequencing; CT: computed tomography; PET: positron emission tomography; MRI:
magnetic resonance imaging; *Obligatory for patients in complete response. **Obligatory for patients with light chain escape, oligosecretory disease, *** SFLC monitoring is
obligatory for patients with light-chain disease. †Obligatory in the case of proteinuria. ††Obligatory when radiographs do not show osteolytic lesions †††PET/CT is required for con-
firmation of minimal residual disease negativity.
The risk of pathological fractures or neurological com-
plications should be assessed in patients with lytic lesions.
In this regard, MRI is the preferred examination to detect
spinal cord compression. If whole-body CT is not avail-
able, conventional radiographs can still be used but must
be interpreted with their limited sensitivity in mind. In
asymptomatic patients without lytic lesions, axial MRI or
whole-body MRI should be considered to assess the pres-
ence of focal lesions (Grade 1B). Addition of dynamic con-
trast enhancement or diffusion weighted imaging to a
whole-body MRI protocol provides additional informa-
tion on BM vascularization, cellularity, and composition
and improves the sensitivity of MRI.50,51 Two or more focal
lesions on MRI are considered as a MM-defining biomark-
er.52 18F-FDG PET/CT can replace whole-body CT, if image
acquisition of CT allows a detailed evaluation of the bone
structures from vertex to knees, including both arms
(Grade 1B).53 18F-FDG PET/CT is important to assess the
presence of extramedullary disease, known to be an inde-
pendent prognostic factor.54 The integration of MRI, PET-
CT and whole-body CT always requires experience, inter-
disciplinary consensus and reflection and needs to be cor-
related with blood, urine and BM results. Finally, baseline
18F-FDG PET/CT scans enable post-treatment follow-up of
hypermetabolic regions with a greater sensitivity than
MRI.54,55 PET/CT is also useful in confirming MRD.56
European Myeloma Network recommendations for the
diagnosis of multiple myeloma: 
The initial work-up should include: complete blood count, kidney
function tests, serum protein electrophoresis with immunofixation,
serum albumin, β2-microglobulin, lactate dehydrogenase, C-reactive
protein, calcium, serum free light chains (especially useful in the case
of light-chain multiple myeloma), 24 h protein collection with protein
quantification, electrophoresis and urine immunofixation, and bone
marrow (aspiration only is acceptable) studies to quantify and char-
acterize abnormal plasmacytosis (Table 2). The intervals between
follow-up studies depend on the response obtained and the patients’
characteristics, as proposed in Table 3 (Grade 2C). After CD138+
plasma cell sorting, fluorescence in situ hybridization analysis should
include at least t(4;14) and del17p; analysis of t(14;16), 1q21 gain
and del(1p32) are also recommended. In addition, bone integrity
needs to be evaluated with whole-body computed tomography and/or
whole-body magnetic resonance imaging (at least axial).
Quantification of the level of plasma cell infiltration, serum free light
chains and magnetic resonance imaging assessment are required to
assess the SLIM-CRAB biomarkers that define early active multiple
myeloma. At relapse, the extent of myeloma-induced bone disease




The variable outcome of MM patients depends on dif-
ferences in disease biology, global disease burden and the
health status of the patient. Researchers have developed
clinical scoring systems in order to estimate individual
prognosis. The degree of anemia, renal failure and osteol-
ysis were the first disease-related prognostic biomarkers
described in MM and were all included in the Salmon &
Durie staging system. Subsequently, β2-microglobulin,
albumin and C-reactive protein levels, and proliferative
activity of MM cells were found to be additional prognos-
tic factors, and albumin and β2-microglobulin levels were
incorporated in the International Staging System (ISS) in
EMN recommendations on MM diagnosis and monitoring
haematologica | 2018; 103(11) 1777
Table 3. Follow-up of multiple myeloma patients according to response and patients’ characteristics (general strength of these recommendation
GRADE 2C). 
Patient risk group               Response to prior                   Blood and urine tests                                              Imaging
                                            treatment
                                                    In CR or VGPR                              Follow-up with blood and urine samples,                      Imaging studies should be performed 
                                                                                                               initially every 1-3 months* with                                      when there are signs of bone disease. 
                                                                                                               gradually increasing intervals                                           Consider PET/CT for high-risk patients
                                                                                                               (max 6 months)                                                                    
General myeloma               In PR                                               Follow-up with blood and urine samples,                     Imaging studies should be performed 
population                                                                                        initially every 1-2 months* with gradually                      when there are signs of bone disease. 
                                                                                                               increasing intervals (max 6 months)                              Consider PET/CT for high-risk patients. 
                                                     With biological progression      Regular follow-up with blood and urine samples,       Imaging using the whole body approach
                                                                                                               initially every month. Consider treatment                     is recommended.
                                                                                                               initiation for patients with high-risk disease                
                                                     Frail patients                                Follow-up with blood and urine samples,                     Imaging directed to the affected region
                                                                                                               every 2 months; if stable increase intervals                 only when signs of progressive bone
Special patient                                                                             to 3 months. Involve family doctor for follow up          disease.
groups                                       LC-MM and patients                   Blood, SFLC and 24 h urine collection.                           Imaging studies should be performed 
                                                     with renal failure                                                                                                                           when there are signs of bone disease
                                                     Patients with                                 Follow-up with SPEP, UPEP and SFLC every                 PET/CT is the preferented technique for
                                                     extramedullary disease             month; if stable, increase intervals to 3 months          follow-up. Recommended every 6 months
                                                                                                                                                                                                                 and obligatory in the case of progression
CR: complete response; VGPR: very good partial response; PR: partial response, PET/CT: positron emission tomography–computed tomograph; max: maximum , SPEP: serum pro-
tein electrophoresis; UPEP: urine protein electrophoresis; SFLC: serum free light chain, LC-MM: light-chain multiple myeloma, 24 h: 24 hours * The monitoring intervals are gen-
erally shorter for patients with high-risk disease (monthly follow-up) than for patients with standard-risk disease (every 2 to 3 months).
2005. Other biomarkers have been identified and include
markers of tumor cell proliferation, cytokines, pro-angio-
genic factors, indicators of bone remodeling, circulating
(exosomal) miRNA and imaging abnormalities. Another
promising biomarker is the serum level of shed B-cell mat-
uration antigen, which correlates well with BM PC infil-
tration and declines according to tumor response.57
Follow-up of serum B-cell maturation antigen levels seems
of interest in patients with non-secretory disease, for
whom we lack reliable parameters in the blood; future
studies are therefore warranted.
Apart from the often still reported Salmon & Durie stag-
ing system, the ISS and revised (R)-ISS are frequently used
as staging systems; in the latter systems, the β2-
microglobulin and albumin levels reflect patients' tumor
burden, turnover rate, presence of renal impairment, and
nutritional and performance status.58 In order to improve
the prognostic performance of the ISS score, the IMWG
updated it, adding high-risk cytogenetics [t(4;14), t(14;16),
and del17p determined by interphase fluorescence in situ
hybridization] and elevated serum lactate dehydrogenase
(Table 4).59 These factors had been previously identified as
relevant risk factors for early progression after autologous
transplantation.60 Of note, the ISS and R-ISS give prognos-
tic information at diagnosis, but have not been validated
in relapsed/refractory MM.
Frailty and co-morbidities
Once a treatment has started, adherence to the estab-
lished protocol remains a major clinical concern in elderly
and frail patients. This requires an individualized
approach in which therapeutic decisions should be driven
by both disease features and the patient’s characteristics.
As in other malignancies, comprehensive geriatric assess-
ments have been evaluated to assess patients’ functional,
cognitive and mental status, comorbidities, nutrition and
presence of geriatric symptoms. Palumbo and co-workers
developed a retrospective simplified geriatric assessment,
named the IMWG-Frailty Index, in which age, the
Charlson Comorbidity Index, activities of daily living and
instrumental activities of daily living were used to dis-
criminate between fit, intermediate-fit and frail patients,
showing different incidences of severe adverse events,
progression-free survival and overall survival.61 Expectedly,
more severe adverse events and treatment discontinua-
tions were reported in frail patients. The most extensive
retrospective and prospective tests and validation analyses
were performed within the German study group, who
prospectively assessed the IMWG-Frailty Index with the
revised Myeloma Comorbidity Index (R-MCI) and other
comorbidity indices.62 A second prospective German
study including 801 MM patients determined that
impaired renal and pulmonary function, poorer Karnofsky
performance status, frailty and age were independent,
multivariate risk factors for overall survival. Addition of
cytogentic abnormalities resulted in the weighted revised
Myeloma Comorbidity Index, which is able to assess
patients' physical condition accurately and is simple to
apply in the clinic.63 Although not yet proven via random-
ized treatment algorithms, there is circumstantial evi-
dence that limited induction therapy, careful dose modifi-
cations and reductions, sensible use of supportive care and
watchful surveillance of unfit and frail patients may
improve patients’ outcome further.64 The EMN insists on
developing  trials, specifically designed for frail patients,
for further refinement of frailty-related diagnostics and
best treatment selection.65
Drug-related biomarkers
While prognostic factors regarding disease evaluation are
listed above, drug-related biomarkers are being assessed to
predict response to treatment and, possibly, to facilitate
optimal treatment while avoiding ineffective therapies and
unnecessary toxicity. Recent pharmacogenomic studies
revealed gene signatures that could predict the clinical out-
come after treatments based on immunomodulatory drugs66
or bortezomib.67 The expression of cereblon, an intracellular
binding partner of immunomodulatory drugs has been
intensively studied as a biomarker and initial studies corre-
lated cereblon levels with the outcome of MM patients
receiving treatment with such drugs.68-71 These studies used
quantitative real time PCR analysis, gene expression profil-
ing or immunohistochemistry to quantify cereblon expres-
sion and showed that loss of cereblon expression was asso-
ciated with resistance to immunomodulatory drugs. Further
investigations revealed limitations of these assays, because
both splice variants of cereblon and point mutations were
described.72,73 When exploring predictors for tumor respons-
es to daratumumab, higher CD38 expression was found on
MM cells of responsive patients. However, good responses
were also seen in patients with lower CD38 expression, an
observation confirmed in a second study that showed that
CD38 expression level was not necessarily predictive of
response in advanced MM; nevertheless attempts to assess
agents that keep CD38 upregulation increased, e.g., all-trans
retinoic acid and histone deacetylase inhibitors, are being
pursued pre-clinically and clinically.74,75
Finally, expression of anti-apoptotic proteins, BCL-2,
BCL-XL or MCL-1, measured by quantitative real-time
PCR, predict pharmacological responses to the bcl-2
inhibitor venetoclax, which is mostly active in patients
harboring t(11,14) translocations.76
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Table 4. The Revised-International Staging System is one of the best stratification methods; it is based on routinely available cytogenetic and biochem-
istry tests (Palumbo et al.).56
R-ISS definitions        Determinants                            Number                    OS (5 years)             Median OS           PFS (5 years)             Median PFS
R-ISS stage I                  ISS stage I, no high-risk CA,       871 (28%)                              82%                               NR                              55%                           66 months
                                          and normal LDH
R-ISS stage II                Other combinations                    1894 (62%)                             62%                        83 months                       36%                           42 months
R-ISS stage III               ISS stage III plus high-risk 
                                          CA or high LDH                              295 (10%)                              40%                        43 months                       24%                           29 months
R-ISS Revised- International Staging System; ISS: International Staging System; OS: overall survival; PFS: progression free survival; CA; cytogenetic abnormalities; LDH: lactate dehy-
drogenase; NR: not reported.
European Myeloma Network recommendations: 
The International Staging System score and, whenever possible, the
Revised International Staging System score, should be determined at
diagnosis to assess prognosis. At least a minimal frailty assessment
should be performed to aid the choice of induction therapy, dose
amendments and supportive care. Although of interest due to their
prognostic and predictive value, biomarkers, such as cereblon and
CD38 protein expression, are not routinely assessed in daily multiple
myeloma care, while fluorescence in situ hybridization for t(11;14)
should be performed if treatment with venetoclax is a clinical option.
Response assessment
The implication of the results of an SFLC assay and MRD
assessment prompted the IMWG to update MM response
criteria.77 In 2011, two new categories, stringent complete
response and very good partial response, were added.
Correct disease assessment is not only crucial for reporting
in clinical trials, it also indicates prognosis in individual
cases.77,78 It is well known that patients who obtain a com-
plete response following induction have improved progres-
sion-free and overall survival after intensive treatment.79
Patients should, therefore, be evaluated before initiation
of each treatment cycle to determine their response to ther-
apy. For MM patients with intact immunoglobulins, the
recommended method for monitoring is quantification of
serum and urinary M-protein. Whether all serum (and
urine) parameters have to be checked after each cycle,
rather than after every two or three cycles is left to the dis-
cretion of each physician, taking into account disease
aggressiveness, organ (i.e. renal) impairment and various
other factors. To confirm a stringent complete response,
normalization of the SFLC values and disappearance of
monoclonal PC infiltration in the BM should be added to
negative immunofixation on serum and urine samples. The
BM must be evaluated in order to confirm a complete
response, but this can be done at some time after the end of
treatment, allowing full recovery of the BM. Of note, BM
infiltration can be heterogeneous with persisting focal
lesions in an otherwise recovered BM (earlier referred to as
patchy disease). The follow-up of patients with light-chain
MM and measurable M-protein levels in urine should
include 24 h urine collections. The SFLC assay generally
allows response assessment in patients with oligosecretory
disease with unmeasurable serum and urine M-protein lev-
els [serum M-protein <1 g/dL (10 g/L) or urine M-protein
<200 mg/24 h]. If the SFLC assay is not informative, BM
plasmacytosis should be assessed.77
The definition of relapse applies to a patient in complete
response who experiences reappearance of MM, while pro-
gression refers to patients with an increasing disease burden
from a baseline or persistent residual disease. An additional
assessment for confirmation is mandatory before initiating
a new line of therapy. MM progression can be determined
biochemically (increase in an existing monoclonal peak), or
by radiological and clinical criteria. The interested reader
can find the criteria for relapse and disease progression
recently described by the IMWG.77 Response assessment
can be challenging, especially in cases of deep response after
the use of monoclonal antibodies, which may interfere
with quantification of the M-protein and may require spe-
cific assays.80
Minimal residual disease
Current induction regimens, in association with autolo-
gous stem cell transplantation, achieve very high
response rates and the responses are often deep.
Unfortunately, however, MM often recurs due to residual
MM cells, drug resistance and/or persistence of resistant
dormant subclones.81 MRD can be assessed by multipara-
meter flow cytometry, polymerase chain reaction (PCR)-
based methods or next-generation sequencing to identify
persistent clonal cells. Recent studies, listed in Table 5,
confirmed the prognostic impact of MRD status as an
independent variable for outcome.82 In the future, MRD
will be more widely used in clinical trials to guide treat-
ment choices and probably as a surrogate marker for pro-
gression-free and overall survival.56
Conventional flow-MRD approaches, based on multi-
ple institutional non-standardized protocols, can reliably
identify malignant PC and discriminate aberrantly
expressed cell surface markers in approximately 90% of
patients (with a sensitivity of detecting 10−4 atypical PC in
normal BM). Recent studies conducted by Spanish and
UK groups have shown that negative MRD by multipara-
meter flow cytometry is predictive for both progression-
free survival and overall survival, even in patients who
achieved a complete response.83,84 Recent technical
advances have increased the sensitivity of next-genera-
tion flow cytometry protocols down to the 10–6 range.85 
MRD analysis by PCR detects persistent residual tumor
cells through the amplification of a tumor-specific molec-
ular marker. The IGH rearrangement is used as a marker
of clonality in various B-cell malignancies.86 Allele-specific
oligonucleotide PCR with primers complementary to the
heavy chain variable sequence remains one of the most
sensitive approaches to detect residual malignant PC,
reaching a sensitivity of 10−5.87 Unfortunately, it is a labo-
rious, time-consuming approach that is not widely avail-
able because of its dependence on patient-specific
primers and probes for quantitative PCR.
Next-generation sequencing of the IGH rearrangement
segments provides insights into the architecture of the B-
lineage repertoire with consensus primers. Since the B-
lineage repertoire includes the malignant PC clone in BM,
next-generation sequencing of IGH enables a quantitative
determination of MRD, without per-patient customiza-
tion, provided that the malignant clone was identified in
a diagnostic sample or a sample taken during active dis-
ease.88 Results from next-generation sequencing are high-
ly concordant with flow-based MRD detection, highly
reproducible and reach a sensitivity of 10−6.89-91 A lack of
standardization and limited commercial availability are
the main restraints for next-generation sequencing. Flow
cytometry and molecular techniques both require an
appropriate BM sample. Heterogeneous BM infiltration
and peripheral blood dilution  can be major hurdles to the
evaluation of MRD. Since neither of these techniques is
able to detect extramedullary disease, they should be
combined with imaging studies. 
Imaging is a third approach to evaluate MRD in MM.
Both PET/CT and MRI have been evaluated in this set-
ting.53,55 Regarding PET/CT, two large studies assessed the
prognostic value of negative PET/CT after induction and
autologous stem cell transplantation.55,92 Both studies
found that PET/CT-negative patients had a better pro-
gression-free and overall survival compared to PET/CT-
positive patients (52 versus 38 months and 5-year esti-
mates of 90% versus 71%, respectively).92 In the French
IMAJEM study, MRD was evaluated in 86 patients via
PET-CT and flow cytometry. Although the concordance
EMN recommendations on MM diagnosis and monitoring
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Table 5. Recent studies on minimal residual disease and the implications for progression-free and overall survival of patients with multiple myeloma.
N.     Reference           Number of     Method       Study                           Patient           Time point               Results                                              Lesson learnt
                                     patients       used for      question                      cohorts          of MRD
                                                           MRD                                                                  assessment
                                                      assessment                                       
#1      Lahuerta et al.,           609                MFC            PFS and OS                     NDMM             9 months after           MRD– prolonged PFS and OS;               MRD– status surpasses CR
           JCO 2017.105                                                              in MRD– pts                                               treatment                    MRD+ in CR similar PFS                         in all risk groups. MRD
                                                                                                                                                                                                          and OS to MRD+ in nCR and PR.           negativity most relevant
                                                                                                                                                                                                                                                                                endpoint for elderly fit 
                                                                                                                                                                                                                                                                                pts with ASCT.
#2      Chakraborty et al.,      185                MFC            PFS and OS in                 NDMM             3 months post-ASCT 56% MRD– with superior OS                  MRD status important
           Biol Blood Marrow                                               post-transplant sCR                                                                       and PFS; del17 pts no difference         markers for survival but
           Transplant 2017.106                                                  patients with HR                                                                             in PFS and OS between                         differs according to
                                                                                             cytogenetic MM                                                                               sCR and MRD–; t(4;14) pts superior    cytogenetics
                                                                                                                                                                                                          PFS and OS in MRD– pts than sCR       
#3      Nadiminti et al.,          100                MFC            Toxicity, safety,               NDMM and     6  months                    MRD– in 85% 6 months after                  MRD and sCR excellent 
           OncoTargets and                                                   PFS and OS of                 pre-treated     post-ASCT                   transplantation, sCR                                markers for PFS and OS
           Therapy 2017.107                                                                                          VTD + HD melphalan                                                                    in 56% and CR in 20%                              
#4      Paiva et al.;                  162                MFC            Monitor MRD in             NDMM             At ID after 9,18           Determines 3 MRD groups,                  MRD is a relevant
           Blood 2016.108                                                          transplant-ineligible     elderly              cycles                            with significant longer                            prognostic factor in
                                                                                             pts                                                                                                       PFS and OS for MRD– group                 elderly and MRD status
                                                                                                                                                                                                                                                                                correlates  with OS and 
                                                                                                                                                                                                                                                                                PFS
#5      Ludwig et al.;                93                 MFC            VTD and VTCD               Untreated       At baseline and          OS and PFS longer in                              MRD surpasses
           BJH 2015.109                                                                                                      induction  in                   MM, elderly     at suspected CR        MRD– vs. MRD+ pts                                   conventional SFLC and
                                                                                             NDMM                                                                                               with BM CR. Same results for              BM CR
                                                                                                                                                                                                          MRD– in VGPR or PR group                    
#6      Roussel et al.;               31                 MFC            VRD induction                Untreated       ID + pre-ASCT,          58% in CR, 68% MRD–.                             None of the MRD– group
           JCO 2014.110                                                              and consolidation         MM,                  post-ASCT,                                                                                        relapsed during a FU of 39
                                                                                             for ASCT pts                    <65 years        post-consolidation,                                                                        months
                                                                                                                                                                   end of treatment                                                                             
#7      Mateos et al.;              260                MFC            VMP vs. VTP as               NMDD,             6 cycles of                   22% MRD– with longer PFS                    MRD surpasses CR and is
           Blood 2014.111                                                          induction                         >65 years        induction                     and OS. VMP better than VTP. 70%      a prognostic factor for OS
                                                                                                                                                                                                          in CR after VMP also MRD– only           and PFS
                                                                                                                                                                                                          45% in VTP group.                                     
#8      Oliva et al.,                   50             MFC and        Consolidation with        NDMM             After 3 and 6               Lower MRD in ASCT vs. CRD pts.         MRD identifies a low-risk
           Oncotarget 2017.112                    ASO-RQ-PCR    ASCT or CRD plus                                    courses of                   Differences between HR vs. SR           group, response
                                                                                             R maintenance                                          maintenance and       and relapse vs. non-relapse pts           independently, better
                                                                                             →MRD                                                      then every                                                                                         characterizes activity
                                                                                                                                                                   6 months till PD                                                                               of treatment.
#9      Puig et al.;                    170            ASO RQ-        Applicability,                    NDMM with     ID and after                MRD assessed in 103 pts.; 54%            ASO RQ-PCR less
           Leukemia 2014.113                          PCR; MFC       sensitivity and                and without   treatment                    MRD+ by PCR, 46% by MFC.                    applicable than MFC but
                                                                                             prognostic                       ASCT                                                        MRD– pts had prolonged PFS                powerful to assess
                                                                                             value of                                                                                              and OS                                                       treatment efficacy and
                                                                                             ASO RQ-PCR                                                                                                                                                        risk stratification
#10    Ferrero et al.;              39                  PCR            MRD kinetics’                NDMM with     ID, study entry,           OS 72% at 8 years median FU               Long-term MRD
           Leukemia 2015.114                                                   impact on survival          ASCT                 after 2 cycles             in MRD– and 48% in MRD+                    monitoring is useful and 
                                                                                                                                                                   CTD, end of                pts. PFS for MRD– 38 months                maintenance therapy
                                                                                                                                                                   treatment, every       and MRD+ 9 months                                 ensures responses
                                                                                                                                                                   6 months until PD                                                                         
#11    Martinez-Lopez          133                MFC            Prognostic value            NDMM             After induction for    MRD– pts had significantly                     MRD surpasses CR and
           et al.; Blood 2014.90                        and NGS        of MRD in pts                                           elderly, after               longer PFS and OS; median                   depth of MRD level
                                                                                             with VGPR after                                        ASCT for                      PFS: MRD≥10-3 27 months,                     showed significant
                                                                                             front-line therapy                                     <65 years                     10-3-10-5 48 months;                                   differences in pts with CR
                                                                                                                                                                                                          <10-5 80 months.                                       
#12    Chari et al.;                  103                NGS            Safety, OS/PFS                ≥2                     Pts in CR or                 29% of pts in CR are MRD–;                    MRD surpasses CR
           Blood 2017.115                                                          and MRD                          treatment       better after
                                                                                                                                        lines                  treatment                                                                                          
#13    Korde et al.;                 45            MFC, NGS,      Tolerability and              NDMM and      ID, achievement         nCR or better pts were                           High rates of MRD
           JAMA Oncol. 2015.116                  FGD-PET/CT    impact on MRD             HR SMM          of CR and/or               MRD– in 100% NDMM /92%                    negativity with longer PFS
                                                                                             negativity                                                   completion of            SMM by MFC, 67%/75% by                      in NDMM/HR SMM
                                                                                                                                                                   cycles 8, 20 and 32,   NGS and 41%/26% by
                                                                                                                                                                   end of treatment       FGD-PET/CT                                              
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between the two tests was low, progression-free survival
was better in patients who were negative according to
both techniques compared to those who were positive by
PET and/or flow cytometry (3-year progression-free sur-
vival, 86.8% versus 52.9%), indicating that both tech-
niques are complementary. A major advantage of PET/CT
is its capacity to assess MRD outside the BM; its disadvan-
tages are high cost and the lack of reimbursement in cer-
tain countries, insufficient standardization and reduced
tracer uptake in some MM patients. Evaluation via
PET/CT has been incorporated into the new IMWG MRD
criteria.77 In the future, the increased capabilities of diffu-
sion weighted MRI to detect small lesions and diffuse
infiltration may offer advantages that merit prospective
evaluation in MRD assessment studies.50
In addition, recent studies have demonstrated that cir-
culating DNA fragments carrying tumor-specific
sequence alterations can be detected and quantified in the
blood of patients with solid tumors.93,94 In MM, various
studies have provided evidence that - much like in solid
tumors - MM-specific alterations (VDJ rearrangements or
somatic genomic alterations) can also be identified and
tracked in cell-free DNA circulating in blood.95,96
European Myeloma Network recommendations: 
Response assessment is an essential part of myeloma manage-
ment. Patients under treatment should be evaluated before the initi-
ation of each cycle and according to international guidelines.
Minimal residual disease testing is not currently recommended in
routine follow-up of patients but is likely to be incorporated in stan-
dard response/progression evaluation soon. Valid options for the
assessment of minimal residual disease are based on bone marrow
cells (next-generation flow cytometry) or molecular analysis (next-
generation sequencing), often also combined with an imaging-based
evaluation. These methods require appropriate expertise.
Conclusion
While novel agents have certainly improved the out-
comes of patients with myeloma, prompt diagnosis and
close follow-up of MM patients remain highly relevant
and contribute to better survival. In most cases, the diag-
nosis of MM is straightforward, being based on biological
and radiological evidence when evocative clinical signs
are present. During response assessment, the evaluation
of MRD will become increasingly important and, within
the next few years, will guide treatment choices in clinical
trials and possibly also outside trial scenarios.
International efforts are needed to standardize the differ-
ent techniques that can be used to evaluate MRD.
Guidelines on appropriate follow-up and patient-tailored
monitoring have been updated in this EMN consensus
paper and should help to improve the outcome and prog-
nosis of our patients.
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#14    Zagmani et al.;             76          FGD-PET/CT    Role of                             NDMM             Baseline, during         PET-negativity post-treatment              PET-CT more careful 
           Clin Cancer                                                            FGD-PET/CT on                                        post-treatment          in 70%, CR in only 53%.                          evaluation of CR.
           Res 2015.92                                                               PFS and OS                                                FU, PD                          PET-negativity influenced PFS              PET-negativity
                                                                                                                                                                                                          and OS favorably.                                     independent predictor 
                                                                                                                                                                                                                                                                                of prolonged PFS/OS
#15    Patriarca et al.,             54          FGD-PET/CT    Prognostic                       AlloSCT pts     Before and/or             Persistence of EMD at                            PET/CT imaging
           Biol Blood Marrow                                               significance of                                          within 6 months         transplantation → poor PFS.                significantly associated
           Transplant 2015.117                                                                                  PET/CT                                                        after alloSCT.              EMD and <CR or VGPR after                with outcome.
                                                                                                                                                                                                          alloSCT →shorter PFS/OS. 
                                                                                                                                                                                                          PET CR pts prolonged PFS/OS.             
#16    Lapa et al.;                    37          FGD-PET/CT    Prognostic                       Pretreated,     At relapse,                   Absence of foci positive factor             Prognostic value of PET/CT
           Oncotarget 2014.118                                                value of FGD-PET/CT    and                   after treatment          for PFS/OS. EMD and intense               in post-SCT relapse
                                                                                                                                        progression                                          uptake associated with                           patients important and 
                                                                                                                                        after SCT                                                shorter PFS/OS. 30% of pts'                  significant impact on
                                                                                                                                                                                                          management changed after PET/CT    pt management
AlloSCT: allogenic stem cell transplantation; ASCT: autologous stem cell transplantation; ASO RQ-PCR: allele-specific oligonucleotide real-time quantitative polymerase chain reaction; BM: bone
marrow; CR: complete remission; CRD: cyclophosphamide, lenalidomide, dexamethasone; d: day; EMD: extramedullary disease; FGD-PET/CT: fluorodeoxyglucose positron emission tomography-
computed tomography; FU: follow-up; HD: high dose; HR: high risk; ID: initial diagnosis; MFC: multiparameter flow cytometry; MM: multiple myeloma; MRD: minimal residual disease; nCR: near-
complete remission; NGS: next generation sequencing; NDMM: newly diagnosed multiple myeloma; OS: overall survival; PCR: polymerase chain reaction; PD: progressive disease; PFS: progression
free survival; PR:  partial remission; pts: patients; R:  lenalidomide; sCR: stringent complete remission; SCT: stem cell transplantation; SFCL: serum free light chain; SMM: smouldering multiple myelo-
ma; SR: standard risk; TTP: time to tumor progression; VGPR: very good partial remission; VMP: bortezomib, melphalan, prednisone; VRD: bortezomib, lenalidomide, dexamethasone; vs.: versus;
VTCD: bortezomib, thalidomide, cyclophosphamide, dexamethasone; VTD: bortezomib, thalidomide, dexamethasone; VTP: bortezomib, thalidomide, prednisone. 
N.     Reference           Number of     Method       Study                           Patients         Time points               Results                                             Lesson learnt
                                     patients       used for      question                      cohort            of MRD
                                                           MRD                                                                  assessment
                                                      assessment                                                             
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